Financial services company Primerica (NYSE: PRI) will be reporting results this Wednesday afternoon. Here’s what to look for.
Primerica beat analysts’ revenue expectations by 1.7% last quarter, reporting revenues of $838.9 million, up 8.9% year on year. It was a satisfactory quarter for the company, with a beat of analysts’ EPS estimates but a miss of analysts’ book value per share estimates.
Is Primerica a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Primerica’s revenue to grow 7.2% year on year to $846.8 million, slowing from the 9.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $5.68 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Primerica has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Primerica’s peers in the life insurance segment, some have already reported their Q4 results, giving us a hint as to what we can expect. CNO Financial Group delivered year-on-year revenue growth of 2.4%, beating analysts’ expectations by 1.5%, and Aflac reported flat revenue, falling short of estimates by 2.9%. CNO Financial Group traded up 5.5% following the results while Aflac was also up 3.4%.
Read our full analysis of CNO Financial Group’s results here and Aflac’s results here.
Investors in the life insurance segment have had fairly steady hands going into earnings, with share prices down 1.2% on average over the last month. Primerica is up 1.1% during the same time and is heading into earnings with an average analyst price target of $298.50 (compared to the current share price of $268.57).
P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.
